ClinicalTrials.gg
Not yet recruitingNCT07599046Updated May 20, 2026

Fecal Microbiota Transplantation (FMT) Combined With Calorie-Restricted Diet and Semaglutide in Patients With Obesity and Type 2 Diabetes

An interventional study of Fecal microbiota transplantation (FMT) and Semaglutide (1 Mg Dose) in Obesity Type 2 Diabetes Mellitus, sponsored by Eighth Affiliated Hospital, Sun Yat-sen University. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by Eighth Affiliated Hospital, Sun Yat-sen University · Not applicable, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 913 studies in Diabetes Mellitus, Type 2 with a site in China — 205 open to participants now, 229 under way, 46 of them phase 3. Diabetes Mellitus, Type 2 · China.

Planned enrollment
730th of 769
20 · median 192
Started
2026
with 88 others
No phase
195 of 913
55 open now
Primary completion
2027-01
later than 115 of 228 live
Registered
828th of 913
by date

Among the 913 studies in Diabetes Mellitus, Type 2 with a site in China, this one is the 730th largest by planned enrollment of the 769 interventional ones that give a count, is one of 89 that started in 2026, is one of 195 with no phase, reaches primary completion later than 115 of the 228 other live ones, and was the 828th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

205 of the 913 studies in Diabetes Mellitus, Type 2 with a site in China are open now. Recruiting first, the newest first:

200 more — sign in →

All 205 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 913 studies in Diabetes Mellitus, Type 2 with a site in China, or all of them as a file.
02

Study summary

Investigation of the efficacy of fecal microbiota transplantation added to calorie-restricted diet and semaglutide versus calorie-restricted diet and semaglutide alone for weight loss and metabolic improvement in patients with moderate to severe obesity and type 2 diabetes mellitus.

Read the detailed description

This study is designed as a single-center, randomized, open-label, parallel-controlled trial. A total of 20 patients with moderate to severe obesity and T2DM (BMI 30-40 kg/m²) whose T2DM duration is less than one year will be enrolled, and randomly assigned to either the intervention group (FMT + ccalorie-restricted diet + semaglutide) or the control group (calorie-restricted diet + semaglutide). The intervention period will be 24 weeks. The primary endpoint is the percentage change in body weight from baseline to post-intervention. Secondary endpoints include the proportion of patients achieving a >5% weight loss, as well as metabolic parameters such as fasting blood glucose, lipid profile, glycated hemoglobin, visceral fat parameters, and gut microbiota diversity (Shannon/Simpson index).

03

Conditions studied

  • Obesity Type 2 Diabetes Mellitus

Keywords

  • Type 2 diabetes mellitus
  • Obesity
  • Fecal microbiota transplantation
  • Calorie-restricted diet
  • Semaglutide
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-60 years;
  2. (BMI) ≥30 kg/m² and \<40 kg/m²;
  3. Duration of type 2 diabetes mellitus \<1 year;
  4. Non-smoker or smoking cessation >3 months;
  5. Voluntary signed with commitment to complete the entire study.

Exclusion criteria

Exclusion Criteria:

  1. Complicated with severe hepatic or renal insufficiency (/aspartate aminotransferase [ALT/AST] >3 times the , or estimated [eGFR] \<60 mL/min/1.73 m²);
  2. Inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), or other organic intestinal diseases; diseases, , or active infections;
  3. Medication and intervention exclusions: Use of α-glucosidase inhibitors, antibiotics, proton pump inhibitors (PPIs), or probiotics/prebiotics within the past 3 months; bariatric surgery within the past 6 months; long-term use of or ;
  4. Others: Pregnant or lactating women; currently participating in other clinical trials.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    Intervention group

    A comprehensive intervention combining fecal microbiota transplantation, calorie-restricted diet, and glucagon-like peptide-1 receptor agonist.

    Biological: Fecal microbiota transplantation (FMT) · Drug: Semaglutide (1 Mg Dose) · Behavioral: Calorie-restricted diet

  • Active comparator
    Control group

    Conventional treatment with calorie-restricted diet and glucagon-like peptide-1 receptor agonist.

    Drug: Semaglutide (1 Mg Dose) · Behavioral: Calorie-restricted diet

Interventions

  • BiologicalFecal microbiota transplantation (FMT)

    Donor Selection: Healthy lean donors with BMI \<23 kg/m² will be selected following rigorous health screening. Capsule Preparation: Donor fecal samples will be homogenized, filtered to remove debris, lyophilized, and encapsulated in enteric-coated capsules. Oral FMT capsule dosage: 10 capsules per dose, once daily, for 6 consecutive days each month.

    Also known as: FMT

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Semaglutide 1.0 mg subcutaneous injection once weekly

    Also known as: glucagon-like peptide-1 receptor agonist, GLP-1 receptor agonist

  • BehavioralCalorie-restricted diet

    Daily caloric intake will be individualized based on physical activity level: 25 kcal/kg/day for individuals with light-to-moderate physical activity and 30 kcal/kg/day for those with heavy physical activity.

    Also known as: CRD

06

What researchers measure

Primary outcomes

  1. Percent change in body weight

    The percentage change in body weight from baseline to follow-up visit (week 24) is presented. Body weight (kg) will be measured using a calibrated electronic scale operated by research personnel who have undergone standardized training.

    Time frame: From enrollment to the end of treatment at 24 weeks

Secondary outcomes

  1. The proportion of participants achieving ≥5% body weight reduction

    The percentage of participants who achieved ≥5% weight reduction from baseline to follow-up visit (week 24) is presented. Body weight (kg) will be measured using a calibrated electronic scale operated by research personnel who have undergone standardized training.

    Time frame: From enrollment to the end of treatment at 24 weeks

  2. Change in glycated hemoglobin (HbA1c)

    Change in glycated hemoglobin (HbA1c) from baseline to week 12 and week 24 is presented. HbA1c (%) values will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  3. Change in fasting insulin

    Change in fasting insulin from baseline to week 12 and week 24 is presented. Fasting insulin (μU/mL) values will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  4. Change in fasting plasma glucose

    Change in fasting plasma glucose from baseline to week 12 and week 24 is presented. Fasting plasma glucose (mmol/L) values will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  5. Change in total cholesterol

    Change in total cholesterol from baseline to week 12 and week 24 is presented. Total cholesterol (mmol/L) values will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  6. Change in low-density lipoprotein cholesterol

    Change in low-density lipoprotein cholesterol from baseline to week 12 and week 24 is presented. Low-density lipoprotein cholesterol (mmol/L) will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  7. Change in high-density lipoprotein cholesterol

    Change in high-density lipoprotein cholesterol from baseline to week 12 and week 24 is presented. High-density lipoprotein cholesterol (mmol/L) will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  8. Change in triglycerides

    Change in triglycerides from baseline to week 12 and week 24 is presented. Triglycerides (mmol/L) values will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  9. Change in uric acid

    Change in uric acid from baseline to week 12 and week 24 is presented. Uric acid (μmol/L) values will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  10. Change in urinary albumin-to-creatinine ratio

    Change in urinary albumin-to-creatinine ratio from baseline to week 12 and week 24 is presented. The albumin-to-creatinine ratio is defined as urinary albumin (mg) divided by urinary creatinine (g). Albumin-to-creatinine ratio (mg/g) values will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  11. Change in high-sensitivity C-reactive protein

    Change in high-sensitivity C-reactive protein from baseline to week 12 and week 24 is presented. High-sensitivity C-reactive protein (mg/dL) values will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  12. Change in gut microbiota diversity indices

    Change in gut microbiota diversity indices (such as Shannon diversity index and Simpson diversity index) from baseline to week 12 and week 24 is presented. The gut microbiota diversity indices will be derived from metagenomic sequencing data.

    Time frame: Baseline, Week 12, and Week 24

  13. Change in fecal short-chain fatty acid concentrations

    Change in fecal short-chain fatty acid concentrations from baseline to week 12 and week 24 is presented. Fecal short-chain fatty acid concentrations (µmol/g wet feces) will be measured by gas chromatography.

    Time frame: Baseline, Week 12, and Week 24

  14. Change in systolic blood pressure

    Change in systolic blood pressure from baseline to week 12 and week 24 is presented. Systolic blood pressure (mmHg) values will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  15. Change in diastolic blood pressure

    Change in diastolic blood pressure from baseline to week 12 and week 24 is presented. Diastolic blood pressure (mmHg) values will be retrieved from the hospital's electronic medical record system.

    Time frame: Baseline, Week 12, and Week 24

  16. Change in body mass index

    Change in body mass index (BMI) from baseline to week 12 and week 24 is presented. BMI is calculated using the formula: BMI = weight (kg) / \[height (m)\]². Height and weight will be measured using a stadiometer and calibrated electronic scale, respectively, operated by research personnel who have undergone standardized training.

    Time frame: Baseline, Week 12, and Week 24

  17. Change in waist circumference

    Change in waist circumference from baseline to week 12 and week 24 is presented. Waist circumference (cm) will be measured using a non-elastic measuring tape operated by research personnel who have undergone standardized training.

    Time frame: Baseline, Week 12, and Week 24

  18. Change in muscle mass

    Change in muscle mass from baseline to week 12 and week 24 is presented. Muscle mass (kg) will be measured using an InBody body composition analyzer operated by research personnel who have undergone standardized training.

    Time frame: Baseline, Week 12, and Week 24

  19. Change in body fat percentage

    Change in body fat percentage from baseline to week 12 and week 24 is presented. Body fat percentage (%) will be measured using an InBody body composition analyzer operated by research personnel who have undergone standardized training.

    Time frame: Baseline, Week 12, and Week 24

  20. Change in visceral fat area

    Change in visceral fat area from baseline to week 12 and week 24 is presented. Visceral fat area (cm²) will be measured using a bioelectrical impedance analyzer operated by research personnel who have undergone standardized training.

    Time frame: Baseline, Week 12, and Week 24

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Jan 2027, 9 months later.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 9 months is below that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
May 20, 2026
StartEst.
Apr 30, 2026
Primary completionEst.
Jan 30, 2027
CompletionEst.
Dec 30, 2029
Last update
May 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07599046
Lead sponsor
Eighth Affiliated Hospital, Sun Yat-sen University
Responsible party
Sponsor
First posted
May 20, 2026
Start date
Apr 30, 2026 (estimated)
Primary completion
Jan 30, 2027 (estimated)
Completion
Dec 30, 2029 (estimated)
Last update
May 20, 2026

Study contacts

Yunfeng Shen, Ph.D
Contact
shenyf26@mail.sysu.edu.cn
0755-83982222

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion